Curbing stem cell tourism in South Africa  by Meissner-Roloff, Madelein & Pepper, Michael S.
Applied & Translational Genomics 2 (2013) 22–27
Contents lists available at ScienceDirect
Applied & Translational Genomics
j ourna l homepage: www.e lsev ie r .com/ locate /atgReviewCurbing stem cell tourism in South Africa☆Madelein Meissner-Roloff, Michael S. Pepper ⁎
Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
Institute for Cellular and Molecular Medicine, University of Pretoria, Pretoria, South Africa☆ This is an open-access article distributed under the t
distribution, and reproduction in any medium, provided th
⁎ Corresponding author at: Dept. of Immunology,
2190; fax: +27 12 319 2946.
E-mail address: michael.pepper@up.ac.za (M.S. Pepp
2212-0661/$ – see front matter © 2013 The Authors. Pu
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
http://dx.doi.org/10.1016/j.atg.2013.05.001a b s t r a c ta r t i c l e i n f oArticle history:
Received 7 December 2012
Received in revised form 8 May 2013
Accepted 8 May 2013
Keywords:
Personalized medicine
Stem cell tourism
Stem cell research
Malpractice
Vulnerable patients
Exploitation
Legislation
RegulationStem cells have received much attention globally due in part to the immense therapeutic potential they harbor.
Unfortunately, malpractice and exploitation (ﬁnancial and emotional) of vulnerable patients have also drawn
attention to this ﬁeld as a result of the detrimental consequences experienced by some individuals that have
undergone unproven stem cell therapies. South Africa has had limited exposure to stem cells and their applica-
tions and, while any exploitation is detrimental to the ﬁeld of stem cells, South Africa is particularly vulnerable in
this regard. The current absence of adequate legislation and the inability to enforce existing legislation, coupled
to the sea of misinformation available on the Internet could lead to an increase in illegitimate stem cell practices
in South Africa. Circumstances are already precarious because of a lack of understanding of concepts involved in
stem cell applications.What ismore, credible and easily accessible information is not available to the public. This
in turn cultivates fears born out of existing superstitions, cultural beliefs, rituals and practices. Certain cultural or
religious concerns could potentially hinder the effective application of stem cell therapies in South Africa and
novelways of addressing these concerns are necessary. Understanding how scientiﬁc progress and its implemen-
tationwill affect each individual and, consequently, the community, will be of cardinal importance to the success
of the ﬁelds of stem cell therapy and regenerative medicine in South Africa. A failure to understand the ethical,
cultural or moral ramiﬁcations when new scientiﬁc concepts are introduced could hinder the efﬁcacy and
speed of bringing discoveries to the patient. Neglecting proper procedure for establishing the ﬁeld would lead
to long delays in gaining public support in South Africa. Understanding the dangers of stem cell tourism –
where vulnerable patients are subjected to unproven stem cell therapies that have not undergone peer review
or been registered with the relevant local authorities – becomes imperative so that strategies to overcome this
threat can be implemented.
© 2013 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Interest in the ﬁeld of translational stem cell (SC) research has
increased rapidly in the past decade, with exciting and promising
research providing hope that cures for previously incurable diseases
may well be attainable in the not too distant future. Much of the excite-
ment originates from the ability of SCs to self-renew, replicate and to
differentiate into any one of the more than 200 cell types in the body.
Although SC therapymay appear to be a relatively newphenomenon,
bone marrow (BM) hematopoietic SCs (HSCs) have in fact been used
routinely for more than 50 years. SCs are grouped into three categories:
embryonic SCs (harvested from a developing blastocyst/embryo pro-
ducedby in vitro fertilization); adult SCs (harvested fromvarious sources
including BM, adipose tissue and umbilical cord blood (UCB)) and
induced pluripotent stem cells (iPSCs — differentiated cells that have
been reverted back to a pluripotent-like state through geneticmodiﬁca-
tion). The best understood are HSCs, which have been successfully ap-
plied around the world in BM transplantation for treatments of
various conditions includingmalignant and non-malignant hematolog-
ical disorders, immune deﬁciencies and certain genetic disorders. How-
ever, with new discoveries of different types of SCs and many potential
novel applications, interest in regenerative and translational medicine
has increased.
One consequence of this interest has been a dramatic rise globally in
companies and clinics that sell stem-cell-related products or services. In
addition to improvement in personal health and wellbeing, the increase
seen in cellular and molecular medicine creates opportunities for entre-
preneurship, business development and employment. South Africa has
great potential for the development of translational medicine involving
SC therapies (Jackson and Pepper, in press). In light of South Africa's cur-
rent burden of disease and the potential for job creation, the country cer-
tainly stands to gain substantially (individually and as an economy) from
these and similar developments. Amajor concern for the implementation
and operation of such companies and clinics would be compliance with
national and international regulatory standards—with the supposed pre-
condition that appropriate national legislation and governance exist.
However, even though SCs harbor the promise of potential cures
for many previously incurable disorders, this promise is easily
exploited, and many questionable SC practices occur in countries
that lack governance and regulation. This has led to the phenomenon
known as “stem cell tourism” (SC tourism), where patients travel
abroad and are subjected to unproven stem cell therapies. These ther-
apies have often not undergone peer review or been registered with
the relevant local authorities and are generally not provided in the
patients' home countries.
Bone marrow transplantation, which is a universally accepted
form of stem cell therapy, has been practiced with success for several
decades in South Africa. Other areas of activity in South Africa in the
stem cell ﬁeld include the growth of skin from small biopsies (mainly
in patients with extensive burns), orthopedic and maxillofacial surgery
and cosmetic surgery. Some work is being done by individual practi-
tioners using mesenchymal stem cells for a variety of conditions. How-
ever, little to no work is being done for the wider spectrum of diseases
for which stem cells have been proposed including neuromuscular
disorders (multiple sclerosis, cerebral palsy etc.) and cardiac disease.
Although it is likely that this situation will be reversed in the near fu-
ture, these currently incurable disorders form the basis of exploitation
seen globally through SC tourism.
An internationally recognized example of SC Tourism involving
South Africa is the case of Stephan van Rooyen and his (now deceased)
girlfriend, Laura Brown. Through their company – initially registered as
Biomark – they sold untested, unproven stem cell therapies to patients
suffering from various illnesses (motor neuron disease and multiple
sclerosis amongst others). They marketed and sold their stem cell
treatments to patients in various countries including the United States,
Switzerland, Holland, Germany, Spain, India, Trinidad, Argentina, Brazil,Mexico, Turkey, Saudi Arabia, Pakistan, China and theUkraine. After Van
Rooyen and Brown's US-based company – Biomark –was shut down by
the Federal District Attorney in 2003, they relocated to South Africa,
changed the name of the company to Advanced Cell Therapeutics
(ACT) from where they continued to sell their treatments in South
Africa and abroad. The couple was charged with 51 indictments by the
Federal grand jury in Atlanta (March 2006) for misconduct in offering
costly (up to $26 000 for a single injection of 1.5 million stem cells)
and unsound SC treatments (Keating, 2006; Rondganger, 2006). How-
ever, by the time they were charged, they were already living in South
Africa. Interpol located the couple at the OR Tambo international airport
in Johannesburg (2007) but they fought the extradition based on a legal
technicality. Laura Brown died of undisclosed causes in 2011 in Cape
Town, while the case against Van Rooyen is still ongoing. If he is to be
found guilty, he could face up to 20 years in prison for committing
fraud, an additional three years per misbranding of drug count, and a
ﬁne of up to $1 million per count (Black, 2007; McNabb, 2011).
It has been more than ten years since these individuals started
their illegitimate practice and justice still has not been served. Their
actions put even more strain on an already overloaded legal system,
costing time and effort which could have been prevented with the
implementation of proper legislation with national and international
ramiﬁcations.
Although SCs appear to hold promise for future therapeutic applica-
tions (in addition to their current accepted applications), around the
globe unscrupulous individuals have started to prematurely promote
bogus “SC cures” for various – still incurable – diseases. They often
portray SCs as the “holy grail” of cell therapies and have created much
uncertainty and controversy in the ﬁeld.
1.1. Concerns of patient exploitation by stem cell tourism
SC tourism is ethically problematic in that it offers unproven thera-
pies that have not undergone peer review or been registered with the
relevant local authorities as legitimate cures for currently incurable
diseases (Master and Resnik, 2011). There exists a large discrepancy be-
tween published, peer reviewed literature and claims posted on these
illegitimate clinics' websites. With SC translation into the clinic (regu-
lated or not) happening at a rapid pace across the world, South
Africans are bound to be exposed to some form of SC treatment sooner
or later. They need to be able to accurately distinguish between legiti-
mate treatments and fraudulent practices and would therefore, at the
minimum, need a creditable source of information to assist them in
making decisions. In light of these obstacles South Africa is vulnerable
to exploitation with regard to SC tourism.
SC tourism has many facets that could lead to multiple pitfalls, each
posing a unique combination of moral, legal, ethical and regulatory
challenges (Strauss, 2010). Hype over false therapeutic claims, ranging
from the sublime to the miraculous, is endangering the entire ﬁeld of
SC therapies. It is hoped that the implementation of strict regulatory
frameworks – such as those established by the Food and Drug Adminis-
tration (FDA) and the International Society for Stem Cell Research
(ISSCR) (Strauss, 2010) –will assist in curtailing these fraudulent prac-
tices. Although the ISSCR has made a patient handbook available on
their website, with information and guidance to patients on how to
evaluate the safety of SC therapies, patients are mostly left to fend for
themselves without the support and concern for safety from regulatory
bodies.
1.2. Mechanisms for promoting stem cell tourism
While having the world at one's ﬁngertips can be tremendously
beneﬁcial, millions of people today are bombarded with a multitude
of options and opinions, leading perhaps to the single most daunting
challenge of the information age: learning to distinguish fact from
ﬁction.
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to gain access to unrestricted information on a virtually unlimited num-
ber of topics. Many companies use the Internet andWeb pages to bring
their business directly to consumers through direct-to-consumer
advertising. However, limited monitoring of content on the Internet
often creates difﬁculties in verifying the accuracy and credibility of the
information presented. This is especially true when it comes to the
ﬁeld of SCs and their current and possible future therapeutic applica-
tions and translation into modern healthcare.
Con men mainly operate by promoting their activities on the
Internet and reach a much broader audience than was possible in a
pre-World-Wide-Web era. They offer false hope, promises of cures
and miracle healings and often advertise unsubstantiated claims on
their Web pages. They play on the needs and desires of emotionally
vulnerable patients to be cured and coax members of the public into
signing up for unproven SC treatments provided in often precarious
settings. Many unsuspecting customers have fallen prey to these illicit
elements, which have the potential to discredit the legitimacy of SC
research and true, current and future therapeutic applications (Lindvall
and Huyn, 2009).
2. Factors that intensify stem cell tourism
2.1. Lag in regulatory oversight
Certain countries havemore strict regulations (e.g. the USAwith the
Federal Drug Agency (FDA)) than others (e.g. China, Mexico, India,
Costa Rica, Thailand etc.), with fewer opportunities for such scams in
the former. Unfortunately, although the South African legislation does
provide some regulatory oversight for the latest advances and discover-
ies concerning SCs, the lack of enforcement of this legislation leads to a
large regulatory gap that could potentially be exploited by opportunistic
and self-serving individuals (Pepper, 2012; Mahomed and Slabbert,
2012). There aremany issues that complicate enforcement of legislation
including a need for educated personnel and contentious deﬁnitions in
national legislation. Even though legislation could serve as a deterrent,
in itself it does not determine whether a practice is ethical or not.
Furthermore, many South Africans have not heard of SCs. Those who
have have mostly been exposed only in passing and have not been
properly informed. This absence of regulatory oversight and the
unavailability of easily accessible, reliable information regarding SCs
and their applications render not only the individuals but also the coun-
try vulnerable to questionable global inﬂuences.
2.2. Lack of proper communication between scientists and the public
A substantial gap exists between scientists and medical doctors
that undertake legitimate SC research and the subsequent accurate
translation of such research to patients. The media often sensational-
izes preliminary scientiﬁc ﬁndings, creating much hype based on
half-truths — dangerous territory that is often exploited by con
men. In the absence of appropriate legislation (either due to lack
thereof or failure to enforce existing legislation), increasing aware-
ness of SCs and their promise in novel therapeutic applications for a
wide range of disorders will undoubtedly bring with it an escalation
in illegitimate SC practices.
3. The moral and scientiﬁc dilemma
SC research has increased exponentially across the globe (Barclay,
2009). Discovering SCs in easily obtainable material such as adipose
tissue and peripheral blood together with less invasive isolation tech-
niques for obtaining these cells (such as umbilical cord blood collec-
tion) has left an open invitation to many undesirable “stem cell
squatters” in the ﬁeld of SC research and translational medicine.The translational process from science to medicine is complex and
slow. Proven treatments involving SCs over the past 50 years include
blood malignancies and other disorders treated with adult SCs through
bone marrow transplantation as well as bone-and skin grafting and
certain corneal diseases or injuries, using adult SCs harvested from the
particular tissue (ISSCR (International Society for Stem Cell Research),
2012).
Legitimate ethically approved clinical research is being conducted in
various registered clinical trials. Although preliminary results seem
positive, very few trials have, to date, successfully completed stage III,
which would be required to bring the therapy or treatment to the
market. The procedures necessary to accredit new treatments are
tedious and painstakingly slow. Furthermore, the media generally fails
to contextualize research ﬁndings into the immediate medical and
scientiﬁc landscape. The vision of a cure or application needs to be tem-
pered with a realistic view on research and regulatory time frames. The
media often sensationalizes optimismwithout considering the context,
which in turn increases the difﬁculty to accurately portray the currently
“do-able” and future treatments to the general public.
In essence, if presented on a sliding scale we have – on the one
hand – scientists doing research ethically and systematically. On the
other hand are scamartists latching onto promising research by offering
unproven treatments to ill, desperate but hopeful patients with a pleth-
ora of research taking place in between these two extremes. With an
increase in awareness of the therapeutic potential of SCs inevitably
comes a surge of illegitimate opportunists. The problem is that research
needs to go through all the right channels before it can beneﬁt patients,
and this is a lengthy process. Patients often don't have the luxury of time
to wait for these treatments to become commercially available or for
potential therapies to go through regulation and accreditation.
Stem cell tourism increases in parallel, as desperate patients are
offered the option of unproven treatments. Furthermore, patients
have a right to access medical treatment and no law forbids them to
undergo treatment of any nature to which they give consent. The end
result is the exodus of frustrated and impatient patients, unwilling to
wait for local approval of SC therapies yet willing to risk their health
and livelihoods on unsubstantiated claims (Caplan and Levine, 2010).
Even though nobody could prevent a desperate patient from wasting
money on unproven therapies, it is the authors' opinion that the very
least we can do is to provide these patients with a platform of knowl-
edge and expertise from which to enquire about potential therapies. A
single trusted source providing unbiased and accurate information re-
garding current available therapies, lists of risks involved with current
therapies and potential risks involved in unproven therapies, could
equip patients with unbiased information to aid their decision making.
Despite repeated warnings from acclaimed scientists against clinics
that offer curative SC therapies for a variety of disorders, many patients
ignore this advice and still opt for treatment (Lau et al., 2008). In addi-
tion, according to Sean Morrison, director of the University of Michigan
Centre for Stem Cell Biology and treasurer of the ISSCR, many doctors
are venturing into their own SC initiatives (Barclay, 2009). Whether
they are compelled to get involved by the steadily increasing patient
demand for SC treatments – only having their patients' best interest at
heart – or not, is hard to decide, since many of these doctors also
stand to gain commercially from the treatments.
Some doctors do however recognize the potential of SC treatments
and instead of subjecting their patients to doubtful practices abroad
would rather opt to treat their patients themselves, where they are
more certain of the type and quality of administered SCs and the
correct application thereof. This not only places them in a moral and
ethical dilemma but also places a degree of risk on their licenses as
practitioners.
It is important to note that not all doctors who offer SC treatments
are imposters. Just the same, as Timothy Caulﬁeld at the University of
Alberta's Health Law Institute, Edmonton, Canada states, people that
offer treatments should publish their data in scientiﬁc, peer-reviewed
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trolled treatments necessitate veriﬁcation of purported results in a
controlled environment through appropriately structured clinical
trials (Cyranoski, 2009). These should include assessments of safety,
efﬁcacy, harvesting, storing/culturing of cell isolates, dosing, administra-
tion procedures and ethically approved information leaﬂets and informed
consent forms (Lindvall and Huyn, 2009). This transparency gives other
researchers the opportunity to verify the claims, safety and efﬁcacy of
the treatment and to advance the ﬁeld through reliable results.
3.1. Emerging stem cell clinics and treatments
The number of clinics that offer SC treatments has increased expo-
nentially in the past four years. In 2009 there were an estimated 200
clinics in China alone and, although it is difﬁcult to determine an
exact number because of the often clandestine nature of their activi-
ties, it is thought that the current estimate well exceeds this number
(Cyranoski, 2009). Clinics are found in various countries. Places such
as China, Mexico, India, Costa Rica, Russia, Thailand, Germany, Hunga-
ry, Korea, the Dominican Republic, Jordan, Kazakhstan and Barbados
are popular destinations, since regulations are generally less strict
or non-existent (Caplan and Levine, 2010).
These clinics offer treatments and cures for still incurable disorders,
including amyotrophic lateral sclerosis, spinal cord injury, stroke,
multiple sclerosis, Parkinson's disease, all forms of blindness including
optic nerve damage, systemic lupus erythematosis, brain injury, cere-
bral palsy, Down's syndrome, Alzheimer's disease, heart disease, diabe-
tes and autism. Of the less serious treatments, cosmetic enhancement is
at the top of the list with anti-aging creams, ﬁbroblast/collagen injec-
tions (as an alternative to botox) or general “health enhancements”
(Lau et al., 2008).
Of particular concern are the cell sources. According to a study
carried out by Lau et al. (2008, it was found that autologous SCs were
provided in nine sites, comprising 47% of their study cohort. Bone mar-
row comprised 37% of autologous cells used (in seven sites) while cells
were also obtained from adipose tissue and blood donations. The other
53% of cells were from other sources such as fetal SCs, cord blood SCs,
and embryonic SCs, peripheral blood, patient fat (adipose tissue),
aborted fetuses, patient's skin, animal tissues, and human placental tis-
sue. Treatments were provided for a wide variety of disorders ranging
from neurological and cardiovascular diseases to allergies. These were
generally treated by SC infusion into cerebrospinal ﬂuid via lumbar
puncture (six sites; 32%), while IV infusion was also common (Lau
et al., 2008).
In addition to the obvious health and safety risks, these clinics often
charge patients exorbitant amounts averaging from $15 000 to $25 000
USD for their SC treatments. Costs are often unsubstantiated and do not
include patient travel or accommodation (Cyranoski, 2009).
3.2. Advocates for stem cell tourism
Advocates for SC treatments do not necessarily endorse SC tourism,
but their fervor to provide treatment often clasheswith opponents of SC
tourism.
Thosewho advocate a patient's right to access all forms of treatment,
potential or real, present the following arguments to support their case:
1. Patients often don't have the luxury of time. Their diseases usually
progress fast and alternative SC treatments (proven or unproven)
are their last option.
2. Clinical trials are costly and ﬁnding appropriate funding for trials is
challenging (Barclay, 2009). In addition, clinical trials prolong the
time until treatments become acceptable and therefore available
to patients.
3. Advocates (some clinicians, researchers or fraudsters) propose that
they have patients' best interests at heart. They work with dyingpatients daily and they claim, consequently, do not have time to
perform studies or write articles that are subjected to peer review.
4. They claim that SC treatments have thus far yielded little or no ad-
verse effects, failing to cite rejection of cells from allogeneic donors.
5. They disagree with the FDA with regard to classiﬁcation of treat-
ments with autologous cells. The FDA classiﬁes all cells that are
more than minimally manipulated as “drugs” that need to adhere
to FDA rules and regulations pertinent to administration of a
“drug”. Conversely, advocates for SC treatments maintain that a
body's own cells are not drugs and should be exempt from FDA
regulatory requirements. Advocates accuse the FDA of stalling devel-
opments in SC treatment since they do not stand to gain directly
from emerging SC treatments and potentially stand to lose proﬁt
because of a shift in medical treatment from pharmaceutical drugs
to cell therapy. A recent example is the case of the FDA against the
Broomﬁeld, Colorado, Clinic, Regenerative Sciences. On 25 July,
2012 the US district court in Washington DC ruled in favor of the
FDAs injunction made in 2010 against Regenerative Sciences. They
had been treating orthopaedic problems with their Regenexx prod-
uct, which the FDA classiﬁes as a drug since cells were more than
minimally manipulated. However, Regenerative Science's medical
director, Dr. Christopher Centeno, plans to appeal the court's deci-
sion and maintains their product is not a drug (Aldhous, 2012). In
the context of this review, South African legislation has not deﬁned
the term ‘minimally manipulated’ nor given deﬁnite regulations
and terms for acceptable SC treatments.
6. Advocates want to capitalize on the favorable climate for new
businesses start-ups in SC treatments. They are afraid of missing
the opportunity provided in the emerging market.
7. Some advocates are driven by the potential fame and recognition
of potentially curing a previously incurable disease with their SC
treatments. They see themselves as pioneers and argue that tech-
nology always precedes regulation.
3.3. Adversaries of stem cell tourism
Adversaries – opponents to unproven SC treatments – are cautiously
optimistic about the potential promises provided by SC treatments.
They do not oppose the development of SC treatments, but rather pro-
pose a safe and regulated environment inwhich to practice and develop
new treatments.
The case against SC tourism centers on the following points:
1. Newdeveloping ﬁeldsmust have a balanced approachwhere ethical,
moral and scientiﬁc principles are applied. Emphasis on scientiﬁc
progress cannot override a scientist's responsibility towards the
public to ensure the release of safe and reliable treatments into the
market. Harmony must exist between risk and beneﬁt that needs
to be obtained through phased and structured assessment of safety,
efﬁcacy, dosing and administration of treatments. Informed consent
procedures must be assessed and approved and all innovation out-
side of research must be demonstrable, scientiﬁc and clinical
(Cyranoski, 2009).
2. Opponents object to unrealistic, incomplete and false marketing
often associated with unproven SC treatments that are made avail-
able to the public. Advertisements are generally over optimistic or
positive, understating potential risks involved, and have numerous
unsubstantiated claims of treatment efﬁcacy without the neces-
sary scientiﬁc proof to back them up (Caplan and Levine, 2010;
Black, 2007).
3. Adversaries object to the lack of transparency from companies pro-
viding SC treatments. At best, selective information ismade available
to patients and the public, creating opportunities for exploitation
(Lau et al., 2008). Furthermore, little or no information is provided
on experimental protocols, procedures or controls that allow for an
independent analysis of the claims (Cyranoski, 2005).
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sessment, proper regulatory oversight and to conform to require-
ments from ethical councils (Lau et al., 2008). Patients are
generally not followed up after treatments and there are no re-
cords kept of potential side effects. Without these measures, it is
impossible to know the lasting effects of treatment, whether po-
tential improvements are due to placebo effects or whether they
are only temporary, and whether there are any side effects related
to the cells administered or their route of harvesting or adminis-
tration. This information is vital to the entire scientiﬁc community
and could aid in developing effective, lasting treatments. With a
lack of FDA-approved clinical trial data, evidence is anecdotal and
controversial at best.
5. Opponents of SC tourismmaintain that false claims of safety and ef-
ﬁcacy of treatmentswill eventually jeopardize legitimate SC research
and its clinical translation. Once public conﬁdence in these treat-
ments is shaken, it will be difﬁcult to convince people otherwise.
6. Another concerning factor is the lack of understanding by providers
of SC treatments of the underlying biology of many of the disorders
and their proposed SC treatments (Barclay, 2009). The fate of
injected cells is not well understood and could lead to serious side
effects or even death.
7. Erroneous therapeutic misconceptions abound and have been
turned into lucrative business models (Cyranoski, 2005). Further-
more, there are no cost regulations or structures for any of the
provided treatments and patients are vulnerable to ﬁnancial
exploitation.
4. How to curb stem cell tourism
Legitimate SC entities could curb malpractice and corruption
through transparency, peer review, clinical trials, by addressing cur-
rent misconceptions with regard to SC therapy and by raising public
awareness of current clinical applications and exploitations of SC
treatments (Lindvall and Huyn, 2009).
This calls for better governance of genuine research and open and
accurate communication from scientists to the public. Creating an
overarching, global, independent regulatory body could be one way
in which to curb the wealth of inaccurate information and criminal
activities on the Internet. This regulatory body could serve as a plat-
form for translating legitimate research through open communication
with the global public. In turn, each country should have its own
regulatory body preferably linked to the global governing body. The
regulatory bodies must follow up on and monitor all therapeutic
claims. They should actively raise public awareness of current SC
therapies and provide an accurate and clear consumer's guide in addi-
tion to physician's or health care provider's guide to approved uses
for cell therapies.
By enabling legitimate SC practices to operate under proper legisla-
tion and simultaneously increasing awareness of these legitimate prac-
tices, one could potentially reduce the appeal offered by illegitimate
practices.
All doctors, scientists and suppliers of SC treatments must adhere
to minimal ethical, scientiﬁc and medical standards for treating
patients with any therapy. Treatment with SCs other than BM or HSCs
is a recent phenomenon where minimal ethical scientiﬁc and medical
standards have, for themost part, not beendeﬁned. The general consen-
sus is to adhere to Global Best/Clinical Practice for safety, efﬁcacy and
ethical regulations. However, because many clinics fail to do so, the
ISSCR has put together a task force and posted proposed minimal stan-
dards, together with a list of guidelines and clinic requirements, on its
website (www.isscr.org) (ISSCR (International Society for Stem Cell
Research), 2012). This includes a list of questions about the treatments
offered that patients could ask the speciﬁc clinics and that ought to be
answered. Through this effort, the ISSCR aims at publishing a list of
clinics that it believes adhere to the minimal standards of operation assuggested by the task force (Taylor et al., 2010). The ISSCRpatient hand-
book could also be used both by patients seeking treatment abroad and
their physicians tomake informed decisions about SC treatment and the
necessary questions to ask the treatment providers prior to signing up
for treatments (ISSCR (International Society for Stem Cell Research),
2012) (http://www.closerlookatstemcells.org).
A similar approach has been taken by the International Cellular
Medicine Society (ICMS). The ICMS has realized that there is virtually
no stopping patients from going abroad for so-called SC treatments
and has therefore opted to encourage doctors and clinics to treat
their patients on the basis of ICMS guidelines, which can be found
on its website (http://www.cellmedicinesociety.org).
Caplan and Levine (Caplan and Levine, 2010) have mentioned
how the neglect from mainstream medicine to act decisively on the
issue of quackery has aggravated the problem, leading to whole coun-
tries purposefully gearing themselves to capitalize even more on the
steady inﬂow of vulnerable patients from abroad. SC tourism is not
a unique phenomenon, but it is potentially posing a much larger
problem than medical tourism since SCs are portrayed as a “single
solution miracle cure” to almost any disease.
5. Conclusion
The vibrant ﬁeld of SC research and treatment consists of dramati-
cally different stakeholders, all of whom have speciﬁc interests and
agendas. For all parties involved, the stakes are high and understanding
the dangers of SC tourism is imperative. It should be pointed out that
the use of the word “tourism” has arisen from the propensity for
patients to travel long distances to receive treatments in foreign coun-
tries. However, the principles outlined above are equally applicable to
activities that may exist in one's own country.
In order to reap the greatest beneﬁt fromwhat SCs have to offer, it is
imperative to understand the current SC milieu. It is necessary to ﬁnd a
balance between scientiﬁc soundness in new discoveries and medical
innovations, and uncontrolled experimental treatments that abuse
patient vulnerability and the regulatory vacuum. The focus should
be on the creation of safe, effective, scientiﬁcally sound treatments in
a controlled regulatory environment without compromising patient
health care. These therapies should furthermore offer patients greater
than – or at least equal – beneﬁt to what conventional available thera-
pies can provide. Unless the therapy provides beneﬁt to the patient, it
will be unethical and thus unacceptable to administer (Lindvall and
Huyn, 2009).
Caplan and Levine (Caplan and Levine, 2010) succinctly summarize
the problem:
Thosewho are drawn to SC therapies are often confused about the inno-
vative status of these interventions, overly reliant on unsubstantiated
claims about the quality of biological material being administered, or
unable to readily locate balanced assessments of what medical tourism
may have to offer for their particular problem. Professional societies and
mainstream SC researchers have an obligation to do more.
In light of these considerations, South Africa is especially vulnerable.
Very few South Africans have access to information regarding SC treat-
ments. In addition, no single credible authoritative voice exists to pro-
vide South Africans with relevant, reliable and accurate information
with regard to current, future or potential SC treatments. There are no
watchful authorities patrolling the SC arena for fraudulent practices or
governing bodies dedicated to the protection and safety of potentially
vulnerable patients (be it locally or inﬂuenced from abroad). Further-
more, physicians and health care providers are not kept abreast of
the current state of affairs in FDA-approved SC treatments nor the
legal application thereof in the South African context.
The global atmosphere around SC treatments underscores the
importance of distinguishing legitimate research and therapeutic
27M. Meissner-Roloff, M.S. Pepper / Applied & Translational Genomics 2 (2013) 22–27application from potential fraudulent practices. As any virus spreads,
so too will the scourges of SC tourism, in this way rendering South
Africa vulnerable to elements that could taint emerging SC research
and therapy in the country.
One manner in which to further legitimate SC practices in South
Africa is by establishing a reliable and easily accessible source of
information, accredited and supported by reputable health and govern-
mental institutions. This information should be freely accessible to the
public, provide reliable information on SC donations and therapeutic
applications and in this way establish safe and appropriate avenues
for regulated SC therapies thatwill allowpatients to distinguish authen-
tic SC therapies from fraudulent practices.
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